Priliximab

Priliximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD4
Clinical data
ATC code	none
Identifiers
CAS Number	147191-91-1^N
ChemSpider	none
^NY (what is this?) (verify)

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease^[1] and multiple sclerosis^[2]^[3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

References

↑ Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut. 40 (3): 320–7. doi:10.1136/gut.40.3.320. PMC 1027080. PMID 9135519.
↑ Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology. 48 (4): 810–6. doi:10.1212/wnl.48.4.810. PMID 9109860.
↑ van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology. 49 (2): 351–7. doi:10.1212/wnl.49.2.351. PMID 9270561.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab Other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Inebilizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 9/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.